<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03321747</url>
  </required_header>
  <id_info>
    <org_study_id>IUSCC-0624</org_study_id>
    <nct_id>NCT03321747</nct_id>
  </id_info>
  <brief_title>Five Fraction SABR Dose Escalation for Early Stage Squamous Cell Carcinoma of the Lung</brief_title>
  <official_title>Phase I/II Trial Evaluating Five Fraction SABR Dose Escalation for Early Stage Squamous Cell Carcinoma of the Lung</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Indiana University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test whether 5 fraction stereotactic ablative body radiation
      (SABR) is safe and improves local control for early state squamous cell carcinoma of the
      lung. While three fraction SABR is effective for the treatment of early stage non small cell
      lung carcinoma (NSCLC) of all histologies, it is not safe for many patients. While four and
      five fraction SABR is safe, recently published data and our institutional data suggests that
      local control for early stage squamous cell carcinoma of the lung using the current four or
      five fraction SABR is suboptimal.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Primary Objectives During Phase I study - Determine the safety and maximum tolerated
           radiation dose for five fraction SABR for squamous cell cancer of the lung.

           During Phase II study - Determine 2 year local control of dose escalated five fraction
           SABR vs. institutional historical control standard dose SABR in squamous cell cancer of
           the lung.

        2. Phase II Secondary Objectives

             -  Determine overall survival, progression free survival and patterns of failure after
                SABR.

             -  Determine tolerability of dose escalated SABR.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 20, 2017</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>This trial is a Phase I/II study designed to determine the maximum tolerated radiation dose and evaluate the efficacy of dose escalated SABR for early stage lung squamous cell carcinoma.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of dose limiting toxicities (DLTs) in each cohort during Phase 1</measure>
    <time_frame>30 days</time_frame>
    <description>Any event per CTCAE v.4 that occurs within 30 days from the start of SABR, and is possibly, probably or definitely related to treatment, and is related to a specific list of symptoms which are outlined in the protocol.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Local control during Phase 2</measure>
    <time_frame>2 years</time_frame>
    <description>Failures will be classified as local failures if failing within or immediately adjacent to the PTV, unless judged by the investigator team to convincingly be a separate lesion from the treated lesion (i.e. new lesion within a planning target volume but across a fissure).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 years</time_frame>
    <description>Length of time start of treatment that patients are still alive</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Phase 1/Dose Level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>11 Gy will be given in 5 fractions for a total dose of 55 Gy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1/Dose Level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 Gy will be given in 5 fractions for a total dose of 60 Gy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1/Dose Level 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>13 Gy will be given in 5 fractions for a total dose of 65 Gy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1/Dose Level 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>14 Gy will be given in 5 fractions for a total dose of 70 Gy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The maximum tolerated radiation dose determined during Phase 1 (i.e. 11, 12, 13, or 14 Gy) will be given in 5 fractions for a total dose of 55, 60, 65, or 70 Gy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Stereotactic Ablative Body Radiation (SABR)</intervention_name>
    <description>Treatments shall not be delivered more frequently than every other day.</description>
    <arm_group_label>Phase 1/Dose Level 1</arm_group_label>
    <arm_group_label>Phase 1/Dose Level 2</arm_group_label>
    <arm_group_label>Phase 1/Dose Level 3</arm_group_label>
    <arm_group_label>Phase 1/Dose Level 4</arm_group_label>
    <arm_group_label>Phase 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          1. Age â‰¥ 18 at time of consent.

          2. Ability to provide written informed consent and HIPAA authorization.

          3. Pathological diagnosis of squamous cell carcinoma of the lung.

          4. Staging PET/CT (invasive mediastinal staging strongly encouraged but not required).

          5. Tumors &lt; 7cm

          6. N0 M0 disease

          7. Baseline PFTs available or will be obtained prior to treatment start

        Exclusion Criteria

          1. Previous radiation therapy to the lung per investigator discretion.

          2. Inability to comply with treatment per investigator discretion.

          3. Inability to follow standard of care follow up recommendations per investigator
             discretion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tim Lautenschlaeger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kathy Lauer</last_name>
    <phone>317-962-3172</phone>
    <email>klauer@iuhealth.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Indiana University Health Hospital</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathy Lauer</last_name>
      <phone>317-962-3172</phone>
      <email>klauer@iuhealth.org</email>
    </contact>
    <investigator>
      <last_name>Tim Lautenschlaeger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana University Health Methodist Hospital</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathy Lauer</last_name>
      <phone>317-962-3172</phone>
      <email>klauer@iuhealth.org</email>
    </contact>
    <investigator>
      <last_name>Tim Lautenschlaeger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana University Melvin and Bren Simon Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathy Lauer</last_name>
      <phone>317-962-3172</phone>
      <email>klauer@iuhealth.org</email>
    </contact>
    <investigator>
      <last_name>Tim Lautenschlaeger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 23, 2017</study_first_submitted>
  <study_first_submitted_qc>October 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 26, 2017</study_first_posted>
  <last_update_submitted>October 25, 2017</last_update_submitted>
  <last_update_submitted_qc>October 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Indiana University</investigator_affiliation>
    <investigator_full_name>Tim Lautenschlaeger</investigator_full_name>
    <investigator_title>Assistant Professor of Radiation Oncology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

